Titan Pharmaceuticals - רווחיות תפעולית TTNP

TTNP (Titan Pharmaceuticals Inc.) - סמל מסחרי של החברה

Titan Pharmaceuticals is developing ProNeura, an advanced subcutaneous drug delivery system for the therapy of CNS disorders. The EBIT margin illustrates profit dynamics, where 0.00 reflects the most recent value of the metric. The company generates revenue from the sale of implants to rehabilitation centers. The current R&D cycle is focused on verifying the safety of long-acting agents, demonstrating steady development without sharp spikes.

TTNP: שיעור רווח תפעולי Titan Pharmaceuticals Inc. 04.07.2022 - 18.10.2025

Titan Pharma - פילוחים אנליטיים ומדדי מפתח (TTNP)

ניתוח מקיף של החברה:titanpharm.com, TTNP
מוצר עיקרי של Titan Pharmaceuticals Inc.

For Titan Pharmaceuticals (TTNP), whose revenues depend on licensing payments and partnerships, the operating margin serves as an indicator of the efficiency of commercializing drug delivery systems. By analyzing the operating margin time series, an investor can see the share of core business profit in revenue before taxes and interest, which allows for an assessment of the model's viability and the timely identification of a value trap.